Huang, Y., Chen, Z., Chen, B., Li, J., Yuan, X., Li, J., Wang, W., Dai, T., Chen, H., Wang, Y., Wang, R., Wang, P., Guo, J., Dong, Q., Liu, C., Wei, Q., Cao, D., & Liu, L
I don't see [GLP-1 agonists] as being any different than other medicine that we use to treat chronic conditions like atherosclerotic heart disease. While the data are not clear about the maintenance of CV benefits in those going off GLP-1 agents, data from mixed diet and lifestyle intervention studies, for example, do suggest that the cardiometabolic benefits of the lost weight may persist out to 5 years, even if some is regained
GLP-1 medications are now a hot topic in weight loss and type 2 diabetes care
Furthermore, it is well-established that many of these species can give rise to secondary oxidants with different reactivity and lifespan than the initial ones (reviewed in Halliwell and Gutteridge, 2015)
[4] The annual economic burden was about US$103 billion in the United States in 2016
A 2023 study in the Journal of the American Medical Association found that only 10% of people with a BMI over 25 manage to lose just 5% of their body weight